INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Objective: An integrated analysis based on the Phase 2 TITAN (NCT01151423) and Phase 3 HERCULES (NCT02553317) studies with caplacizumab (CPLZ) in acquired thrombotic thrombocytopenic purpura (aTTP) was performed to assess treatment differences on efficacy and safety outcomes that may have been undet...
Guardado en:
Autores principales: | Flora Peyvandi, Spero Cataland, Marie Scully, Paul Coppo, Paul Knoebl, Johanna A. Kremer Hovinga, Ara Metjian, Javier de la Rubia, Katerina Pavenski, Jessica Minkue Mi Edou, Filip Callewaert, Hilde De Winter |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/50e75989ab3e4389a9bb0fcf5b02f584 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
COVID-19 and thrombotic thrombocytopenic purpura: A review of literature
por: Balraj Singh, et al.
Publicado: (2021) -
EPIDEMIOLOGY, TREATMENT PATTERNS, AND CLINICAL OUTCOMES AMONG PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) IN THE UNITED STATES: AN ELECTRONIC HEALTH RECORDS ANALYSIS
por: Ayoade Adeyemi, et al.
Publicado: (2021) -
Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era.
por: Andry Van de Louw, et al.
Publicado: (2021) -
A Rare Association of Thrombotic Thrombocytopenic Purpura with Systemic Lupus Erythematosus in a Sudanese Woman: Case Report
por: Ibn Idris Rodwan AA, et al.
Publicado: (2021) -
THE OUTCOME OF IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDHOOD AND THE RISK FACTORS FOR CHRONICITY
por: Barış YILMAZ, et al.
Publicado: (2021)